Virginia Commonwealth University
Investigating the Regulation of Epithelial-Mesenchymal Transition through Fibronectin-Mediated TGF-β1 Mechanotransduction using in vitro models of Triple-Negative Breast Cancer
Abstract
dc:description.abstractTGF-β1 is a potent regulator of epithelial-mesenchymal transtion (EMT), a cellulartransdifferentation process that promotes cellular motility and matrix remodeling, critical to tumorigenesis and metastasis. TGF-β1-induced EMT promotes the assembly of FN, which synergistically binds latent TGF-β1 to aid in its activation. The purpose of of this work is to further probe the effects of autocrine TGF-β1 signaling during EMT progression by utilizing CRISPR-Cas9 deletion of the TGFB1 gene in in vitro models of triple-negative breast cancer. The studies outlined in this work demonstrate that autocrine TGF-β1 maintains a baseline level of mesenchymal marker expression. It also functions to desensitize TGF-β receptors, reducing their capacity to signal from sharp, excessive boluses of active TGF-β1, while stillpotentiating further TGF-β1 signaling for EMT progression. We also highlight a a keydifference in FN assembly capacity across malignancy, with TGF-β1low epithelial cells, that can readily create small FN thin fibrils, while TGF-β1high TNBC cells, which secrete higher levels of FN, do not assemble them into FN matrices nearly as readily. Autocrine TGF-β1 is critical for the assembly of FN fibrils, particularly in TGF-β1low epithelial cells. Wedemonstrate that even empty LAP, the complex used to hold the TGF-β1 dimer latent in the ECM, has the ability to induce some degree of FN assembly. Lastly, through extended EMT-induction, we demonstrate how TGF-β1 is critical for the irreversible commitment to a mesenchymal phenotype. The body of this details the just how tightly autocrine TGF-β1 regulates EMT-associated processes, but also highlights an important facet of growth-factor signaling regulation by the ECM. Future experimentation to more thoroughly understand the growth-factor-ECM signaling axes will help inform the identification of future targets for therapeutic intervention, not only in triple-negative breast cancer, but in a host of othersolid tumors and and fibrotic disease states.
Degree
thesis:*- Name thesis:degree_name
- Doctor of Philosophy
- Level thesis:degree_level
- Dissertation
- Discipline thesis:degree_discipline
- Biomedical Engineering
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Sofroniou, Michael M
- https://orcid.org/0000-0002-9380-5806
- Contributors dc:contributor
-
- Christopher A. Lemmon, Ph.D.
- Rebecca L. Heise, Ph.D.
- Paula D. Bos, Ph.D.
- Priscilla Y. Hwang, Ph.D.
- Gregory S. Walsh, Ph.D.
Subjects
dc:subject × 8Rights
dc:rights- Statement dc:rights
-
- © The Author
Identifiers
dc:identifier.*- Identifier
- https://scholarscompass.vcu.edu/etd/7629